Highlights

  • EBO shares closed at $18.57, down 2.06% on 24 August 2026
  • FY2026 full-year results released on 19 August
  • Revenue reached approximately NZ$13.49 billion, an increase of 9.9%
  • EBITDA rose 7.8%, with an annual report, investor presentation and Dividend announcement included

EBOS Group Ltd (ASX:EBO) shares closed at $18.57, down 2.06% on 24 August 2026. The stock remains in focus as the healthcare distribution and animal-health company works through its FY2026 full-year results and continues to navigate cost pressures across its diversified operations.

About EBOS Group Ltd

EBOS Group Ltd is a diversified healthcare distribution and animal-health company operating across Australia and New Zealand, with a Business model built around the large-scale distribution of pharmaceuticals, medical products and animal-health supplies. The company's scale allows it to service a broad customer base spanning pharmacies, hospitals, veterinary clinics and other healthcare providers, positioning EBOS as a critical link within the regional healthcare and animal-health Supply chains. This distribution-focused business model tends to provide relatively defensive Earnings characteristics, given the consistent underlying Demand for pharmaceuticals and healthcare products regardless of broader economic conditions. EBOS has also built out complementary businesses within its animal-health division, providing further Diversification beyond its core human-healthcare distribution operations. The company's long operating history and scale advantages across Australia and New Zealand have made it one of the more significant healthcare infrastructure businesses in the region, with growth historically supported by both organic Volume increases and selective acquisitions that expand its service offering and geographic reach.

Key Developments

EBOS Group released its FY2026 full-year results on 19 August, reporting Revenue of approximately NZ$13.49 billion, an increase of 9.9%, while EBITDA rose 7.8%, figures that demonstrate continued growth across the company's core distribution and animal-health businesses. The healthcare distribution and animal-health company continues to benefit from its scale across Australia and New Zealand, with the latest results reflecting the advantages of its established market position and diversified revenue base. The latest result also included the company's annual report, investor presentation and dividend announcement, providing shareholders with a comprehensive update on the business's financial position, strategic priorities and capital-management approach. EBOS remains focused on its diversified healthcare and pharmaceutical distribution operations, which provide relatively defensive earnings characteristics compared to more cyclical sectors of the market. Investors are assessing whether the company can maintain this earnings growth while managing cost pressures, an important consideration given the scale of EBOS's distribution network and the operational challenges that can arise from managing large logistics and supply-chain operations. The company's continued expansion of its healthcare platforms will also be an important Factor in sustaining growth over the medium term.

Conclusion

EBOS Group's FY2026 full-year results, marked by solid revenue and EBITDA growth, reinforce the company's position as a key healthcare distribution and animal-health business across Australia and New Zealand. While the share price decline on the day suggests some investor caution, the underlying growth in revenue and earnings points to continued momentum across EBOS's diversified platforms. Ongoing cost management and the successful expansion of its healthcare and animal-health operations will remain key factors in sustaining this growth trajectory.